To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act to extend the period for a first applicant, with respect to a generic drug, to obtain tentative approval without forfeiting the 180-day exclusivity period, and for other purposes.
The bill’s titles are written by its sponsor.
Mar 29, 2012
112th Congress, 2011–2013
Died in a previous Congress
This bill was introduced on March 29, 2012, in a previous session of Congress, but was not enacted.
Representative for New Jersey's 6th congressional district
Read Text »
Last Updated: Mar 29, 2012
Length: 7 pages
This is the first step in the legislative process.
H.R. 4332 (112th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 112th Congress, which met from Jan 5, 2011 to Jan 3, 2013. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). H.R. 4332 — 112th Congress: Generic Drug Application Review Fairness Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/hr4332
“H.R. 4332 — 112th Congress: Generic Drug Application Review Fairness Act of 2012.” www.GovTrack.us. 2012. February 21, 2017 <https://www.govtrack.us/congress/bills/112/hr4332>
|title=H.R. 4332 (112th)
|accessdate=February 21, 2017
|author=112th Congress (2012)
|date=March 29, 2012
|quote=Generic Drug Application Review Fairness Act of 2012
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.